Post-CEI meeting  “Biomarkers for Immunotherapies in Cancer”

This meeting took place on November 12, 2018 and was co-organized by KIM “Biomarkers & Therapy” and the Eurobiomed competitiveness cluster. It was the logical continuation of the Call for Expression of Interest (CEI) launched on March 12, 2018  targeting clinicians, biologists, researchers, and other industry stakeholders with the objective of identifying clinical situations demonstrating a need for new biomarkers and new detection methods.
This theme was selected by the KIM Committee from a total of 29 proposals received.

Programme

4:00 PM: Welcome participants

Introduction
Laurent Garnier: Presentation of the Eurobiomed cluster
Prof. Sylvain Lehmann, Brigitte Couette: Presentation of the KIM “Biomarkers & Therapy”

The challenge of immunotherapy follow-up, the clinician’s point of view
Prof. William Jacot – ICM

Partnership offers by industry
Fabienne Hermitte – VP, Medical Affairs – HalioDx
Jean-Philippe Coton – Managing Director – Histalim
Sarah Nocchi – International Research Manager – Abreos

Research overview
Pierre Martineau – IRCM
Nathalie Bonnefoy – IRCM
Prof. Frédéric Bibeau – CHU Caen
Philippe Rondard – IGF

Access to biological resources
Dr. Jean-Pierre Bleuse – ICM – Director of Clinical Research, Translational Research, and Innovation; Manager of the Montpellier Biological Resource Center (CRB)
Edouard Bosvert, Coordinator of the LR OccitanieBiobank network

7:30 PM: Cocktail & networking

The successful event brought together 57 participants and 19 companies, including Horiba, closing with an afterwork activity serving as an opportunity to establish new collaborations.